Sutro, Celgene collaborate on R&D of antibody drugs

12/19/2012 | Genetic Engineering & Biotechnology News

Sutro Biopharma agreed to design and develop new antibody-drug conjugates and bispecific antibodies against two undisclosed targets for Celgene using its cell-free protein synthesis technology. The deal also covers the production of a proprietary Celgene antibody. In return, Celgene will give Sutro an upfront payment and as much as $500 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN